Chlamydia pneumoniae DNA is present in peripheral blood mononuclear cells during acute coronary syndrome and correlates with chlamydial lipopolysaccharide levels in serum
- 1 January 2009
- journal article
- Published by Taylor & Francis in Scandinavian Journal of Infectious Diseases
- Vol. 41 (3) , 201-205
- https://doi.org/10.1080/00365540902737968
Abstract
Chlamydia pneumoniae can possibly trigger and maintain inflammation in coronary arteries. Chlamydia pneumoniae DNA and chlamydial lipopolysaccharide (cLPS) were measured 3 times during a 1-y period in 97 patients with acute coronary syndrome. Chlamydia pneumoniae DNA in peripheral blood mononuclear cells was detected in 8 (8.2%) patients at the initial hospitalization and in 9 (10.6%) patients at 3 months. One y after the acute coronary syndrome, Chlamydia pneumoniae DNA was not found in any patients. Serum cLPS levels were elevated at inclusion, and declined significantly during follow-up (1.40 microg/ml; (0.20-2.91), median; (range of 25th to 75th percentiles) at inclusion, 0.44 microg/ml; (0.00-1.39) at 1 y; ANOVA p<0.0001). cLPS levels correlated significantly to Chlamydia pneumoniae DNA positivity at 3 months (p=0.003). In conclusion, Chlamydia pneumoniae DNA is present during acute coronary syndrome and in the recovery period, but declines in stable state, suggesting a role of the bacterium in the acute phase of coronary syndrome.Keywords
This publication has 25 references indexed in Scilit:
- Novel enzyme immunoassay utilizing lipopolysaccharide-binding protein as a capture molecule for the measurement of chlamydial lipopolysaccharide in serumDiagnostic Microbiology and Infectious Disease, 2006
- Effect of Simvastatin, an Established Lipid-Lowering Drug, on Pulmonary Chlamydia pneumoniae Infection in MiceAntimicrobial Agents and Chemotherapy, 2005
- A 6 week course of azithromycin treatment has no beneficial effect on atherosclerotic lesion development in apolipoprotein E-deficient mice chronically infected with Chlamydia pneumoniaeJournal of Antimicrobial Chemotherapy, 2005
- Heat shock protein 60 autoimmunity and early lipid lesions in cholesterol-fed C57BL/6JBom mice during Chlamydia pneumoniae infectionAtherosclerosis, 2004
- Hydroxymethylglutaryl Coenzyme A Reductase Inhibition Reduces Chlamydia pneumoniae -Induced Cell Interaction and ActivationCirculation, 2003
- Effect of 3 Months of Antimicrobial Treatment With Clarithromycin in Acute Non–Q-Wave Coronary SyndromeCirculation, 2002
- Autoimmunity to Human Heat Shock Protein 60, Chlamydia pneumoniae Infection, and Inflammation in Predicting Coronary RiskArteriosclerosis, Thrombosis, and Vascular Biology, 2002
- StandardizingChlamydia pneumoniaeAssays: Recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada)Clinical Infectious Diseases, 2001
- The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniaeJournal of Clinical Investigation, 1999
- Detection of Chlamydia pneumoniae and Chlamydia psittaci in sputum samples by PCR.Journal of Clinical Pathology, 1993